高级搜索
58例局限期食管小细胞癌治疗分析[J]. 肿瘤防治研究, 2013, 40(12): 1183-1186. DOI: 10.3971/j.issn.1000-8578.2013.12.017
引用本文: 58例局限期食管小细胞癌治疗分析[J]. 肿瘤防治研究, 2013, 40(12): 1183-1186. DOI: 10.3971/j.issn.1000-8578.2013.12.017
Clinic Therapy to Primary Esophageal Small Cell Carcinoma with Limited Disease[J]. Cancer Research on Prevention and Treatment, 2013, 40(12): 1183-1186. DOI: 10.3971/j.issn.1000-8578.2013.12.017
Citation: Clinic Therapy to Primary Esophageal Small Cell Carcinoma with Limited Disease[J]. Cancer Research on Prevention and Treatment, 2013, 40(12): 1183-1186. DOI: 10.3971/j.issn.1000-8578.2013.12.017

58例局限期食管小细胞癌治疗分析

Clinic Therapy to Primary Esophageal Small Cell Carcinoma with Limited Disease

  • 摘要: 目的 探讨原发性食管小细胞癌的不同治疗方法的疗效。方法 回顾性分析58例局限期食管小细胞癌,其中手术联合化疗18例,序贯放化疗23例,同步放化疗17例,采用Kaplan-Meier及Log rank 法分析其生存时间,并探讨三种方法的失败原因。结果 手术联合术后化疗组中位生存期为15.2月,其1、2及3年生存率分别为66.7%、33.3%及16.7%;序贯放化疗组中位生存期为17.3月,其1、2及3年生存率分别为69.6%、39.1%及21.7%,与手术联合组比较差异无统计学意义;同步放化疗组中位生存期为25.8月,其1、2及3年生存率分别为82.4%、52.9%及35.3%,与手术联合化疗组及序贯放化疗组,同步放化疗组生存时间明显延长。失败的主要原因是远处转移和局部复发,其中手术联合术后化疗组有15例出现远处转移;序贯放化疗组中有18例出现远处转移,与手术联合化疗组比较差异无统计学意义(P>0.05);同步放化疗组有9例出现远处转移,较手术联合化疗组及序贯放化疗组低,差异有统计学意义(P<0.05)。结论 对局限期原发食管小细胞癌同步放化疗疗效较好,治疗失败的主要原因是远处转移。

     

    Abstract: Objective To investigate the effect of different treatment to Primary esophageal small cell carcinoma. Methods Fifty-eight patients with limit disease(LD) primary esophageal small cell carcinoma were collected from several hospital from Jan. 2000 to Jan. 2010. Eighteen cases of the 58 patients were treated by surgery +postoperative chemotherapy, twenty-three cases by non-concurrent radio-chemotherapy, and seventeen cases by concurrent chemo-radiotherapy. The Kaplan-Meier and log-rank methods were used to estimate survival time. Results The median survival time of surgical combined with chemotherapy was 15.2months; the 1-,2- and 3-year survival rates were 66.7%,33.3%and 16.7% respectively ; the median survival time of non- concurrent chemo-radiotherapy was 17.3 months; the 1-, 2- and 3-year survival rates were 69.6%, 39.1% and 21.7% respectively; the median survival time of concurrent chemo-radiotherapy was 25.8 months; the 1-, 2- and 3-year survival rates were 82.4%, 59.2% and35.3% respectively. Distant metastases of the surgical combined with chemotherapy, non- concurrent chemo-radiotherapy and concurrent chem.-radioyherapy, were 15 cases, 15 cases and 9 cases respectively. The local recurrence of the surgical combined with chemotherapy was higher than that of concurrent chem-radiotherapy(10 cases vs. 4 cases). Conclusion Concurrent chemo-radiotherapy was effective treatment to limit disease (LD) primary esophageal small cell carcinoma, and the reason of recurrence was distant metastases.

     

/

返回文章
返回